Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C
NCT ID: NCT00948220
Last Updated: 2011-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
26 participants
INTERVENTIONAL
2003-07-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy
NCT01045278
Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy
NCT01120795
Nutritional Support During Antiviral Therapy for Hepatitis C
NCT00841243
Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy
NCT00682591
Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs
NCT03820102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Chronic hepatitis C patients on standard antiviral therapy with peginterferon alfa-2a and ribavirin
peginterferon alfa-2a and ribavirin
standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
Control
Chronic hepatitis C patients without standard antiviral therapy
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
peginterferon alfa-2a and ribavirin
standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged between 18 and 65
* male patients
Exclusion Criteria
* renal disease
* hyperparathyroidism
* hypogonadism
* malignant disease
* use of any other drug known to effect bone mineral metabolism
* use of alcohol
* organ transplant
* any form of thyroid disease
* any medical condition known to be associated with bone loss
18 Years
65 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
University of Ulm
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Universitätsklinikum Ulm
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Fuchs, MD
Role: PRINCIPAL_INVESTIGATOR
University of Ulm
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Ulm
Ulm, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OSTEO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.